H2O

H2O Health outcomes observatory

Summary

Today, many measures of disease (and disease outcomes) are based largely on input from clinicians. As such they do not fully capture patients’ own experiences of the disease and its impact on their lives.

The aim of H2O is to create ‘health outcomes observatories’ that will amplify the patient voice both in their own healthcare and in healthcare systems more broadly.

The health outcomes observatories will work by providing patients with digital tools, including an app, to report their health outcomes in a standardised way. Patients will always maintain control of their own data and will decide who can access it. At one level, the information will help clinicians and patients to make better decisions on their care.

Meanwhile, the data will be anonymised and tracked so that individual patients and their clinicians can compare their progress with other patients with similar health issues. This aggregated data could also form the basis of research into new, innovative, evidence-based treatments.

The project will focus on setting up health outcomes observatories in four countries (Germany, Spain, the Netherlands, and Austria) covering three disease areas: diabetes, inflammatory bowel disease, and cancer. In the longer term, the project hopes that more observatories, covering a wider range of disease areas, will open up across Europe.

Participants

  Show participants on map
EFPIA companies
  • Abbvie Inc, North Chicago, Illinois, United States
  • Astrazeneca AB, Södertälje, Sweden
  • Eli Lilly And Company LTD, Basingstoke, United Kingdom
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • Medtronic International Trading SARL, Tolochenaz, Switzerland
  • Novartis Pharma AG, Basel, Switzerland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
  • Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland
Universities, research organisations, public bodies, non-profit groups
  • Charite - Universitaetsmedizin Berlin, Berlin, Germany
  • Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
  • Forum Des Patients Europeens, 1040, Belgium
  • Institut Catala De La Salut, Barcelona, Spain
  • Katholieke Universiteit Leuven, Leuven, Belgium
  • King'S College London, London, United Kingdom
  • Medizinische Universitaet Wien, Vienna, Austria
  • Region Stockholm, Stockholm, Sweden
  • Stichting Integraal Kankercentrum Nederland, Utrecht, Netherlands
  • The European Institute For Innovation Through Health Data, Gent, Belgium
  • Universita Vita-Salute San Raffaele, Milano, Italy
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Team - It Research SL, Barcelona, Spain
  • The Hyve BV, Utrecht, Netherlands
Associated partners
  • Jdrf International, New York, United States
  • Trial Nation, Copenhagen, Denmark
Third parties
  • Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron (Vhio), Barcelona, Spain

Participants
NameIHI funding in €
Charite - Universitaetsmedizin Berlin1 189 508
Erasmus Universitair Medisch Centrum Rotterdam1 279 661
Forum Des Patients Europeens450 413
Institut Catala De La Salut1 016 008
Katholieke Universiteit Leuven458 188
King'S College London680 000
Medizinische Universitaet Wien2 181 474
Region Stockholm548 375
Stichting Integraal Kankercentrum Nederland563 813
Team - It Research SL562 813
The European Institute For Innovation Through Health Data564 625
The Hyve BV567 500
Universita Vita-Salute San Raffaele333 063
 
Third parties
NameFunding in €
Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron (Vhio)81 250
 
Total Cost10 476 691